Recurrent Pancreatic Carcinoma Completed Phase 2 Trials for Selumetinib (DB11689)

Also known as: Pancreatic carcinoma recurrent / Pancreas carcinoma recurrent / Pancreatic cancer recurrent

IndicationStatusPhase
DBCOND0043478 (Recurrent Pancreatic Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01658943Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyTreatment